RecruitingNCT07686263
KarXT versus placebo for relapse prevention in schizophrenia
About this title
Read the official source — NCT07686263Medication studyAges 18–65Multiple countries
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
Depending on the assigned group, you receive KarXT (xanomeline/trospium chloride) or a placebo, an inactive comparison treatment.
- Listed locations
- Bentonville and 53 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 20, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 472
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Argentina, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07686263
- Official title
Show the full official title
A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Bentonville, United States · Little Rock, United States · Rogers, United States
43 more locations
- Anaheim, United States
- Bellflower, United States
- Culver City, United States
- Garden Grove, United States
- La Habra, United States
- Lemon Grove, United States
- Montclair, United States
- Orange, United States
- Pico Rivera, United States
- Redlands, United States
- Riverside, United States
- Torrance, United States
- Boynton Beach, United States
- Hollywood, United States
- Miami, United States
- Miami Lakes, United States
- Miami Springs, United States
- Oakland Park, United States
- Atlanta, United States
- Sandy Springs, United States
- Savannah, United States
- Chicago, United States
- Gaithersburg, United States
- Cincinnati, United States
- Oklahoma City, United States
- Austin, United States
- Richardson, United States
- Río Cuarto, Argentina
- Buenos Aires, Argentina
- Córdoba, Argentina
- Santiago del Estero, Argentina
- Novi Iskar, Bulgaria
- Brno, Czechia
- Klecany, Czechia
- Warsaw, Poland
- Bialystok, Poland
- Poznan, Poland
- Brașov, Romania
- Bucharest, Romania
- Barcelona, Spain
- Valladolid, Spain
- Zamora, Spain
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
Does this study involve medication?
Yes. The study involves medication, including Xanomeline/Trospium Chloride and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....